Bronchodilator responsiveness in normal infants and young children

Amy B. Goldstein, Robert G. Castile, Stephanie Davis, David A. Filbrun, Robert L. Flucke, Karen S. McCoy, Robert Tepper

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Several studies have demonstrated that normal infants exhibit bronchoconstriction after inhalation of nonspecific agonists and that the induced airway narrowing can be reversed by the inhalation of a β-agonist. However, there are very limited data on baseline airway tone and the airway response to a β-agonist in this subject population. The purpose of our study was to evaluate in normal infants baseline airway responsiveness to the inhaled β-agonist, albuterol, using changes in maximal expiratory flows. Forty-one healthy infant volunteers with no history of respiratory disease or recurrent wheezing (ages 5.4 to 141.4 wk) were studied. Maximal expiratory flow-volume curves were obtained at baseline and 10 min after inhalation of albuterol (n = 28) or placebo (n = 13) using a metered-dose inhaler with a spacer. The mean percent change was significantly greater (p <0.05) in the albuterol versus placebo group for FEV0.5 (2.2% versus -1.5%), FEF75% (10.6% versus -3.1%), and FEF85% (12.9% versus 0.5%). Six of 28 albuterol-treated infants demonstrated increases in FEF75% greater than two standard deviations from the mean change in FEF75% seen in the placebo group. These infants were younger and more frequently exposed to maternal smoking during pregnancy. We conclude that normal healthy infants have overall levels of baseline airway tone that are similar to that reported in adults and older children; however, among the infants we evaluated the response to an inhaled bronchodilator was greatest in the youngest infants and in those exposed to tobacco smoking.

Original languageEnglish (US)
Pages (from-to)447-454
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume164
Issue number3
StatePublished - Aug 1 2001
Externally publishedYes

Fingerprint

Bronchodilator Agents
Albuterol
Inhalation
Placebos
Maximal Expiratory Flow-Volume Curves
Smoking
Metered Dose Inhalers
Bronchoconstriction
Respiratory Sounds
Healthy Volunteers
Mothers
Pregnancy
Population

Keywords

  • Airway responsiveness
  • Asthma
  • Bronchodilator
  • Infant pulmonary function
  • Tobacco smoke

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Goldstein, A. B., Castile, R. G., Davis, S., Filbrun, D. A., Flucke, R. L., McCoy, K. S., & Tepper, R. (2001). Bronchodilator responsiveness in normal infants and young children. American Journal of Respiratory and Critical Care Medicine, 164(3), 447-454.

Bronchodilator responsiveness in normal infants and young children. / Goldstein, Amy B.; Castile, Robert G.; Davis, Stephanie; Filbrun, David A.; Flucke, Robert L.; McCoy, Karen S.; Tepper, Robert.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 164, No. 3, 01.08.2001, p. 447-454.

Research output: Contribution to journalArticle

Goldstein, AB, Castile, RG, Davis, S, Filbrun, DA, Flucke, RL, McCoy, KS & Tepper, R 2001, 'Bronchodilator responsiveness in normal infants and young children', American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 3, pp. 447-454.
Goldstein AB, Castile RG, Davis S, Filbrun DA, Flucke RL, McCoy KS et al. Bronchodilator responsiveness in normal infants and young children. American Journal of Respiratory and Critical Care Medicine. 2001 Aug 1;164(3):447-454.
Goldstein, Amy B. ; Castile, Robert G. ; Davis, Stephanie ; Filbrun, David A. ; Flucke, Robert L. ; McCoy, Karen S. ; Tepper, Robert. / Bronchodilator responsiveness in normal infants and young children. In: American Journal of Respiratory and Critical Care Medicine. 2001 ; Vol. 164, No. 3. pp. 447-454.
@article{6f663df6c6394fe0b623a6ef9717502a,
title = "Bronchodilator responsiveness in normal infants and young children",
abstract = "Several studies have demonstrated that normal infants exhibit bronchoconstriction after inhalation of nonspecific agonists and that the induced airway narrowing can be reversed by the inhalation of a β-agonist. However, there are very limited data on baseline airway tone and the airway response to a β-agonist in this subject population. The purpose of our study was to evaluate in normal infants baseline airway responsiveness to the inhaled β-agonist, albuterol, using changes in maximal expiratory flows. Forty-one healthy infant volunteers with no history of respiratory disease or recurrent wheezing (ages 5.4 to 141.4 wk) were studied. Maximal expiratory flow-volume curves were obtained at baseline and 10 min after inhalation of albuterol (n = 28) or placebo (n = 13) using a metered-dose inhaler with a spacer. The mean percent change was significantly greater (p <0.05) in the albuterol versus placebo group for FEV0.5 (2.2{\%} versus -1.5{\%}), FEF75{\%} (10.6{\%} versus -3.1{\%}), and FEF85{\%} (12.9{\%} versus 0.5{\%}). Six of 28 albuterol-treated infants demonstrated increases in FEF75{\%} greater than two standard deviations from the mean change in FEF75{\%} seen in the placebo group. These infants were younger and more frequently exposed to maternal smoking during pregnancy. We conclude that normal healthy infants have overall levels of baseline airway tone that are similar to that reported in adults and older children; however, among the infants we evaluated the response to an inhaled bronchodilator was greatest in the youngest infants and in those exposed to tobacco smoking.",
keywords = "Airway responsiveness, Asthma, Bronchodilator, Infant pulmonary function, Tobacco smoke",
author = "Goldstein, {Amy B.} and Castile, {Robert G.} and Stephanie Davis and Filbrun, {David A.} and Flucke, {Robert L.} and McCoy, {Karen S.} and Robert Tepper",
year = "2001",
month = "8",
day = "1",
language = "English (US)",
volume = "164",
pages = "447--454",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Bronchodilator responsiveness in normal infants and young children

AU - Goldstein, Amy B.

AU - Castile, Robert G.

AU - Davis, Stephanie

AU - Filbrun, David A.

AU - Flucke, Robert L.

AU - McCoy, Karen S.

AU - Tepper, Robert

PY - 2001/8/1

Y1 - 2001/8/1

N2 - Several studies have demonstrated that normal infants exhibit bronchoconstriction after inhalation of nonspecific agonists and that the induced airway narrowing can be reversed by the inhalation of a β-agonist. However, there are very limited data on baseline airway tone and the airway response to a β-agonist in this subject population. The purpose of our study was to evaluate in normal infants baseline airway responsiveness to the inhaled β-agonist, albuterol, using changes in maximal expiratory flows. Forty-one healthy infant volunteers with no history of respiratory disease or recurrent wheezing (ages 5.4 to 141.4 wk) were studied. Maximal expiratory flow-volume curves were obtained at baseline and 10 min after inhalation of albuterol (n = 28) or placebo (n = 13) using a metered-dose inhaler with a spacer. The mean percent change was significantly greater (p <0.05) in the albuterol versus placebo group for FEV0.5 (2.2% versus -1.5%), FEF75% (10.6% versus -3.1%), and FEF85% (12.9% versus 0.5%). Six of 28 albuterol-treated infants demonstrated increases in FEF75% greater than two standard deviations from the mean change in FEF75% seen in the placebo group. These infants were younger and more frequently exposed to maternal smoking during pregnancy. We conclude that normal healthy infants have overall levels of baseline airway tone that are similar to that reported in adults and older children; however, among the infants we evaluated the response to an inhaled bronchodilator was greatest in the youngest infants and in those exposed to tobacco smoking.

AB - Several studies have demonstrated that normal infants exhibit bronchoconstriction after inhalation of nonspecific agonists and that the induced airway narrowing can be reversed by the inhalation of a β-agonist. However, there are very limited data on baseline airway tone and the airway response to a β-agonist in this subject population. The purpose of our study was to evaluate in normal infants baseline airway responsiveness to the inhaled β-agonist, albuterol, using changes in maximal expiratory flows. Forty-one healthy infant volunteers with no history of respiratory disease or recurrent wheezing (ages 5.4 to 141.4 wk) were studied. Maximal expiratory flow-volume curves were obtained at baseline and 10 min after inhalation of albuterol (n = 28) or placebo (n = 13) using a metered-dose inhaler with a spacer. The mean percent change was significantly greater (p <0.05) in the albuterol versus placebo group for FEV0.5 (2.2% versus -1.5%), FEF75% (10.6% versus -3.1%), and FEF85% (12.9% versus 0.5%). Six of 28 albuterol-treated infants demonstrated increases in FEF75% greater than two standard deviations from the mean change in FEF75% seen in the placebo group. These infants were younger and more frequently exposed to maternal smoking during pregnancy. We conclude that normal healthy infants have overall levels of baseline airway tone that are similar to that reported in adults and older children; however, among the infants we evaluated the response to an inhaled bronchodilator was greatest in the youngest infants and in those exposed to tobacco smoking.

KW - Airway responsiveness

KW - Asthma

KW - Bronchodilator

KW - Infant pulmonary function

KW - Tobacco smoke

UR - http://www.scopus.com/inward/record.url?scp=0035422191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035422191&partnerID=8YFLogxK

M3 - Article

C2 - 11500348

AN - SCOPUS:0035422191

VL - 164

SP - 447

EP - 454

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -